Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn&apos;s disease

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

Aliment Pharmacol Ther.

Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M

doi: 10.1111/apt.14943.

Inflammatory Bowel Disease

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clin Gastroenterol Hepatol.

Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X

doi: 10.1016/j.cgh.2016.11.023.

Inflammatory Bowel Disease

Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study

United European Gastroenterol J.

Tai FWD, Ellul P, Elosua A, Fernandez-Urien I, Tontini GE, Elli L, Eliakim R, Kopylov U, Koo S, Parker C, Panter S, Sidhu R, McAlindon M

doi: 10.1177/2050640620948664.

Inflammatory Bowel Disease

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis.

Barnes EL, Long MD, Kappelman MD, Martin CF, Sandler RS

doi: 10.1093/ibd/izy378.

Inflammatory Bowel Disease

Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies

Gut.

Khalili H, Håkansson N, Chan SS, Chen Y, Lochhead P, Ludvigsson JF, Chan AT, Hart AR, Olén O, Wolk A

doi: 10.1136/gutjnl-2019-319505.

Inflammatory Bowel Disease

Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease

J Crohns Colitis.

Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL

doi: 10.1093/ecco-jcc/jjaa039.

Inflammatory Bowel Disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis

Clin Gastroenterol Hepatol.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R

doi: 10.1016/j.cgh.2018.12.040.

Inflammatory Bowel Disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European Gastroenterol J.

Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A

doi: 10.1177/2050640619873784.

Gastroenterology

Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease

Related content

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease

Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies

Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease